ArticleBreast cancer research : BCR2025
Transfer learning drives automatic HER2 scoring on HE-stained WSIs for breast cancer: a multi-cohort study.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundStreamlining the clinical procedure of human epidermal growth factor receptor 2 (HER2) examination is challenging. Previous studies neglected the intra-class variability within both HER2-positive and -negative groups and lacked multi-cohort validation. To address this deficiency, this study collected data from multiple cohorts to develop a robust model for HER2 scoring utilizing only Hematoxylin&Eosin-stained whole slide images (WSIs).
methodsA total of 578 WSIs were collected from five cohorts, including three public and two private datasets. Each WSI underwent adaptive scale cropping. The transfer-learning-based probabilistic aggregation (TL-PA) model and multi-instance learning (MIL)-based models were compared, both of which were trained on Cohort A and validated on Cohorts B-D. The model demonstrating superior performance was further evaluated in the neoadjuvant therapy (NAT) cohort. Scoring performance was assessed using the area under the receiver operating characteristic curve (AUC). Correlation between the model scores and specific grades (HER2 levels, pathological complete response (pCR) status, residual cancer burden (RCB) grades) were evaluated using Spearman rank correlation and Dunn's test. Patch analysis was performed with manually defined features.
resultsFor HER2 scoring, the TL-PA significantly outperformed the MIL-based models, achieving robust AUCs in four validation cohorts (Cohort A: 0.75, Cohort B: 0.75, Cohort C: 0.77, Cohort D: 0.77). Correlation analysis confirmed a moderate association between model scores and manual reader-defined HER2-IHC status (Coefficient
conclusionTL-PA shows robust generalization for HER2 scoring with minimal data; however, it still inadequately capture intra-class variability. This indicates that future deep-learning endeavors should incorporate more detailed annotations to better align the model's focus with the reasoning of pathologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.